Physician profile
Arun Kumar
NPI 1023017761
$3,592.11
in general payments reported to CMS, 2019-2025
23 companies · $997 in 2025
The $997 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $547 · 2021: $107 · 2022: $254 · 2023: $581 · 2024: $772 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.11 |
| Education | $154.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,426.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $465.38 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $362.20 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $334.44 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $142.73 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Astellas Pharma US INC | $141.19 | 2023-2025 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $110.75 | 2025 | Voquezna |
| Optinose US, INC. | $85.70 | 2024-2025 | |
| Dexcom, INC. | $76.86 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $70.26 | 2019-2021 | |
| Pfizer INC. | $54.93 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.00 | 2023 | |
| Allergan, INC. | $51.63 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $37.02 | 2022-2025 | |
| Sanofi Pasteur INC. | $26.40 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $24.97 | 2024 | Aptima |
| Kowa Pharmaceuticals America, INC. | $22.20 | 2023 | Seglentis |
| Celgene Corporation | $21.92 | 2019 | |
| Shire North American Group INC | $19.85 | 2019 | |
| Abbvie INC. | $19.74 | 2020 | |
| Ibsa Pharma INC. | $17.00 | 2025 | Tirosint, Flector, Licart |
| Shield Therapeutics INC | $15.06 | 2024 | |
| Exact Sciences Corporation | $13.61 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.